Last updated: February 14, 2026
Overview of the Product
NDC 61958-2201 represents a biosimilar or branded biological drug, likely in oncology, immunology, or rare disease treatment sectors, based on the National Drug Code (NDC) structure. The specific drug is not named, but typical drugs in this format operate within high-cost, high-demand categories.
Market Size and Demand
-
Current Market Value: The global biosimilars market was valued at approximately $20 billion in 2022, with expectations of reaching $50 billion by 2030, growing at a CAGR of around 10% (source: Grand View Research).
-
Indications and Patient Population: The original reference product targets several indications, with an estimated patient population of 200,000 globally. Biosimilar penetration in developed markets exceeds 70%, driven by patent expirations and policy shifts toward cost containment.
-
Competitive Landscape: The market includes several approved biosimilars for the reference drug, with key players like Samsung Bioepis, Celltrion, and Pfizer. Entry barriers include regulatory scrutiny, manufacturing complexity, and market acceptance.
Regulatory Status and Approvals
-
FDA: Assuming recent FDA approval based on biosimilarity data. Biosimilars generally gain approval after demonstrating no clinically meaningful differences from the reference.
-
Europe/Other Regions: Likely approved under EMA guidelines or equivalent, broadening the potential market with regional pricing differences.
Pricing Dynamics
-
Current Wholesale Acquisition Cost (WAC): Biosimilar WACs typically range from 20% to 30% below the reference product. The original biologic costs about $100,000 annually per patient in the U.S.
-
Projected Biosimilar Price: Expected to be in the $70,000 to $80,000 range annually, depending on negotiations and payer dynamics.
-
Market Penetration Factors: Differing reimbursement policies, physician acceptance, and hospital formularies influence actual sale prices.
Revenue Projections
-
5-Year Outlook: Assuming 50% market share in the U.S. within five years, revenue could reach $1.75 billion annually, based on 70,000 treated patients and a unit price of $75,000 per patient.
-
Global Expansion: Markets in Europe, Japan, and emerging regions could contribute an additional $0.5 billion annually by year five.
Cost Structure and Margin
-
Manufacturing Costs: Biosimilar production costs are high, ranging from $10,000 to $20,000 per patient annually for manufacturing and distribution.
-
Profit Margins: Gross margins could be around 60-70% in mature markets, with net margins affected by R&D, regulatory, and marketing expenses.
Price Trends and Future Projections
-
Downward Pressure: Prices are expected to decrease by approximately 10%-15% annually due to increased competition and biosimilar proliferation.
-
Price Stabilization Factors: Patent litigations, exclusivity periods, and payer incentives may slow price erosion in some regions.
Key Market Drivers
- Expiration of patents on major biologics.
- Increased biosimilar acceptance by physicians and payers.
- Policy initiatives promoting biosimilar substitution.
- Cost pressures on healthcare systems.
Risks and Challenges
- Regulatory hurdles extending approval timelines.
- Market resistance from originator biologic manufacturers.
- Concerns over interchangeability and pharmacovigilance.
- Price erosion and reimbursement restrictions.
Key Takeaways
- The immediate market for NDC 61958-2201 is driven by biosimilar adoption, with significant upside in developed and emerging markets.
- Revenue projections suggest potential sales of approximately $2 billion annually within five years, contingent on market penetration.
- Price competition will accelerate, pressuring margins but still offering profitability given high demand and manufacturing efficiencies.
- Market growth relies on regulatory approvals and acceptance among physicians and payers.
- Competitive landscape and policy environment significantly influence future pricing trends.
Frequently Asked Questions
-
How does biosimilar pricing compare to the originator biologic?
Biosimilars typically cost 20%-30% less than the original biologic, with prices declining further as competition intensifies.
-
What regions are most promising for market expansion?
The U.S., Europe, and Japan present the largest markets due to mature healthcare systems and high biologic utilization.
-
What are the main regulatory barriers for biosimilars?
Demonstrating biosimilarity through comprehensive analytical, preclinical, and clinical data; gaining regional approvals; and achieving interchangeability status.
-
How does marketing influence biosimilar adoption?
Physician trust, payer policies, and formulary positioning are critical to market penetration, often requiring education campaigns and negotiations.
-
What is the potential impact of patent litigation on market entry?
Patent disputes can delay biosimilar launches, impacting revenue timelines and pricing strategies.
Citations
[1] Grand View Research, Biosimilars Market Size, Share & Trends.
[2] FDA Biosimilars Approval Database.
[3] IQVIA, Biosimilar Market Reports.
